Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML

Bone Marrow Transplantation volume 43, pages 685–692 (2009)Cite this article

Abstract

Lymphocyte and platelet recovery may influence outcomes of allo-SCT for treatment of AML. It is not clear, however, if this impact is independent of patient and transplant characteristics. To investigate this question, we evaluated the influence of pre- or post transplant factors on day +30 absolute lymphocyte count (ALC) and the speed of platelet engraftment. We studied 106 AML patients treated with fludarabine and melphalan reduced-intensity conditioning and allo-SCT. Twenty nine percent of patients were in CR at the initiation of the conditioning, 39% had active disease with circulating blasts and 32% had active disease without circulating blasts. The graft source was peripheral blood from a matched sibling donor in 55% and BM from a matched unrelated donor in 45%. Our data showed that the presence of circulating blasts before transplantation is significantly correlated with low post-SCT day +30 ALC and slow platelet engraftment. This finding suggests that the impact of early ALC and platelet recovery on transplant outcome may not be independent of disease status at transplantation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Tallman MS, Gilliland DG, Rowe JM . Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154–1163.

    Article  CAS  PubMed  Google Scholar 

  2. Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant 2004; 33: 419–423.

    Article  CAS  PubMed  Google Scholar 

  3. Chakrabarti S, Brown J, Guttridge M, Pamphilon DH, Lankester A, Marks DI . Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback. Bone Marrow Transplant 2003; 32: 23–30.

    Article  CAS  PubMed  Google Scholar 

  4. Dominietto A, Raiola AM, van Lint MT, Lamparelli T, Gualandi F, Berisso G et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001; 112: 219–227.

    Article  CAS  PubMed  Google Scholar 

  5. Einsele H, Ehninger G, Steidle M, Fischer I, Bihler S, Gerneth F et al. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 1993; 82: 1672–1678.

    CAS  PubMed  Google Scholar 

  6. Kim DH, Kim JG, Sohn SK, Sung WJ, Suh JS, Lee KS et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 2004; 125: 217–224.

    Article  PubMed  Google Scholar 

  7. Kim DH, Sohn SK, Jeon SB, Baek JH, Kim JG, Lee NY et al. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow Transplant 2006; 37: 101–108.

    Article  CAS  PubMed  Google Scholar 

  8. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 2001; 28: 951–956.

    Article  CAS  PubMed  Google Scholar 

  9. Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ et al. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia 2003; 17: 1865–1870.

    Article  CAS  PubMed  Google Scholar 

  10. Nash RA, Gooley T, Davis C, Appelbaum FR . The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Oncologist 1996; 1: 371–380.

    CAS  PubMed  Google Scholar 

  11. Pavletic ZS, Bishop MR, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997; 15: 1608–1616.

    Article  CAS  PubMed  Google Scholar 

  12. Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J . Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481–3486.

    CAS  PubMed  Google Scholar 

  13. Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006; 107: 1688–1695.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007; 13: 454–462.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052–3059.

    Article  CAS  PubMed  Google Scholar 

  16. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865–872.

    Article  CAS  PubMed  Google Scholar 

  17. de Lima M, Champlin RE, Thall PF, Wang X, Martin III TG, Cook JD et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 2008; 22: 258–264.

    Article  CAS  PubMed  Google Scholar 

  18. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326–2331.

    Article  CAS  PubMed  Google Scholar 

  19. Heining C, Spyridonidis A, Bernhardt E, Schulte-Monting J, Behringer D, Grullich C et al. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Bone Marrow Transplant 2007; 39: 613–622.

    Article  CAS  PubMed  Google Scholar 

  20. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380–3389.

    Article  CAS  PubMed  Google Scholar 

  21. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007; 110: 4543–4551.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Dolstra H, Van de Wiel-van Kemenade E, De Witte T, Preijers F . Clonal predominance of cytomegalovirus-specific CD8+ cytotoxic T lymphocytes in bone marrow recipients. Bone Marrow Transplant 1996; 18: 339–345.

    CAS  PubMed  Google Scholar 

  23. Ozdemir E, St John LS, Gillespie G, Rowland-Jones S, Champlin RE, Molldrem JJ et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002; 100: 3690–3697.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge our patients and clinical staff, without whom this research would not have been possible. We have no conflict of interest to disclose. This study was supported, in part, by grants to KVK from the National Institutes of Health (RO1 CA109326) and the Leukemia and Lymphoma Society (Translational Research Program 6178-06).

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    R M Saliba, K V Komanduri, S Giralt, J de Souza, G Rondon, R E Champlin & M de Lima

  2. Department of Hematology and Oncology, Syrian Lebanese Hospital, Sao Paulo, Brazil

    P Patah

  3. Division of Hematology and Oncology, Boston University Medical Center, Boston, MA, USA

    B Oran

  4. Tennessee Oncology, Sarah Cannon Cancer Center, Blood and Marrow Transplantation, Nashville, TN, USA

    D Couriel

Authors
  1. R M Saliba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K V Komanduri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J de Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Patah
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Oran
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Couriel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Rondon
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R E Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M de Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M de Lima.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saliba, R., Komanduri, K., Giralt, S. et al. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant 43, 685–692 (2009). https://doi.org/10.1038/bmt.2008.376

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.376

Keywords

This article is cited by

Search

Advanced search

Quick links